KILITCH.NS Stock Analysis
KI
Avoid
Based on Eyestock quantitative analysis, KILITCH.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Undervalued
Kilitch Drugs (India) Ltd. engages in the manufacture and sale of pharmaceuticals, medicinal chemical, and botanical products. The company is headquartered in Mumbai, Maharashtra and currently employs 153 full-time employees. The firm is primarily engaged in the development, manufacturing, and marketing of finished dosages. The Company’s products portfolio includes Parenteral and Nasal Products, Oral, Effervescent, Nutritional Products, Medical Devices, and Cosmetics and Herbal Products. Its Parenteral and Nasal Products has a range of products that help in gastroenterology, anti-inflammatory, anti-malaria, diagnostic, uterine stimulants, veterinary and many other areas in the form of ampoules and vials. The Company’s range of oral formulations includes tablets, capsules, dry syrups and oral powders. The Company’s medical devices offer a C-Seal brand. The company has a range of cosmetics ranging from oil, lotion and liquid to cream and paste in skin care, personal care, and hair care category. The firm has its manufacturing units located in India and Ethiopia.